检索结果-南通市图书馆

Antiviral therapy in cytomegalovirus-positive ulcerative colitis:A systematic review and meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第10期20卷 2695-2703页

作者： Uri Kopylov Noa Eliakim-Raz Andrew Szilagy Ernest Seidman shomron ben-horin Lior Katz Department of Gastroenterology Sheba Medical Center Tel Hashomer Ramat Gan 5262 Israel Division of Gastroenterology McGill University Health Center Montreal Quebec H3G 1A4Canada Sackler School of Medicine Tel-Aviv University Ramat-Aviv Tel-Aviv 69978Israel Department of Medicine E Beilinson Hospital Rabin Medical Center Petach Tikva 49100 Israel Division of Gastroenterology Jewish General Hospital McGill University Montreal Quebec H3T 1E2Canada

AIM: To evaluate the impact of antiviral treatment on cytomegalovirus (CMV)-positive ulcerative colitis patients.

关键词： Ulcerative colitis Cytomegalovirus Colectomy Antiviral treatment Gancyclovir Foscarnet

Cytomegalovirus positive ulcerative colitis:A single center experience and literature review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Pathophysiology 2013年第1期4卷 18-23页

作者： Uri Kopylov Gila Sasson Bella Geyshis Michal Tepperberg Oikawa Iris Barshack Rami Eliakim shomron ben-horin Department of Gastroenterology Sheba Medical CenterRamat Gan 52621Israel Internal Medicine D Sheba Medical CenterRamat Gan 52621Israel Central Virology Laboratory Public Health LaboratoriesIsrael Ministry of HealthRamat Gan 52621Israel Department of Pathology Sheba Medical CenterRamat Gan 52621Israel

AIM:To compare the clinical outcome of cytomegalovirus(CMV)-positive ulcerative colitis(UC) patients with and without antiviral ***:This was a retrospective case-controlled *** database of UC patients in our institution was scanned for documented presence of CMV on colonic ***,clinical data,endoscopy findings and pathology reports were extracted from the patients' charts and electronic *** available,the data from colonoscopies preceding and following the diagnosis of colonic CMV infection were also *** primary outcomes of the study were colectomy/death during hospitalization and the secondary outcomes were colectomy/death through the course of the ***:Thirteen patients were included in the study,7(53.5%) of them were treated with gancyclovir and 6(46.5%) were *** treated with antivirals presented with a more severe disease and 57% of them were treated with cyclosporine or infliximab before initiation of gancyclovir,while none of the patients without antivirals required rescue *** patient died and another patient underwent urgent colectomy during hospitalization,both of them from the gancyclovir-treatment *** the entire follow-up time(13 ± 13 mo),a total of 3 colectomies and one death occurred,all among the antiviral-treated patients(for colectomy:3/7 vs 0/6 patients,P = 0.19;for combined adverse outcome:4/7 vs 0/6 patients,P = 0.07).In 9/13 patients,immunohistochemistry for CMV was performed on biopsies obtained during a subsequent colonoscopy and was positive in one patient ***:Gancyclovir-treated patients had a more severe disease and outcome,probably unrelated to antiviral ***-CMV-positive patients with mild disease may recover without antiviral therapy.

关键词： Ulcerative colitis Cytomegalovirus Gancyclovir Cyclosporine Immunohistochemistry

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2017年第16期23卷 2995-3002页

作者： shomron ben-horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein Department of Gastroenterology Sheba Medical CenterSackler School of MedicineTel-Aviv UniversityRamat-Gan 52621Israel the First Affiliated Hospital of Sun Yat-Sen University Guangzhou 510700Guangdong provinceChina Department of Gastroenterology and Hepatology Inflammatory Bowel Disease ServiceRoyal Adelaide HospitalSchool of MedicineUniversity of AdelaideAdelaideSA 5005Australia Division of Gastroenterology School of Health SciencesUniversity of IoanninaIoannina 45500Greece Department of Gastroenterology Hepatology and NutritionDigestive Disease Diseases and Surgery InstituteCleveland Clinic FoundationClevelandOH 44109United States Unit of Inflammatory Bowel Disease Hospital Israelita Albert EinsteinSao PauloSP 05652-900Brazil Department of Gastroenterology Venizeleio General HospitalHeraklion71409 CreteGreece Department of Internal Medicine Yonsei University College of MedicineSeoul 03722South Korea NIHR Nottingham Digestive Diseases Biomedical Research Unit Nottingham University Hospitals NHS Trust and University of NottinghamNottingham NG7 2UHUnited Kingdom Dipartimento di Medicina Interna e SpecialitàMediche “Sapienza”University of Rome00185 RomaItaly Comprehensive Digestive Institute of Nevada Las VegasNV 89113United States Department of Gastroenterology and Hepatology Soroka University Medical CenterBeer-Sheva 6400111Israel Department of Gastroenterology University Hospital ZvezdaraBelgrade 11000Serbia Department of Gastroenterology University-Hospital of Saint-Etienne42100 Saint EtienneFrance Gastroenterology Unit S.Orsola-Malpighi40138 BolognaItaly IBD Clinical and Research Centre University of ManitobaWinnipegMB R3T2N2Canada

AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients.

关键词： Inflammatory bowel disease Corticosteroids 5-aminosalicylates Ulcerative colitis

Significance of low level infliximab in the absence of anti-infliximab antibodies

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第6期21卷 1907-1914页

作者： Bella Ungar Adi Anafy Henit Yanai Yulia Ron Miri Yavzori Orit Picard Ella Fudim Ronen Loebstein Uri Kopylov Yehuda Chowers Iris Dotan Rami Eliakim shomron ben-horin Department of Gastroenterology Sheba Medical Center Tel Hashomer and Sack-ler School of Medicine Tel-Aviv University IBD Center Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Sackler School of Medicine Tel-Aviv University Institute of Clinical Pharmacology Sheba Medical Center Tel Hashomer and Sackler School of Medicine Tel-Aviv University Rambam Health Care Campus and Bruce Rappaport School of Medicine Technion Institute of Technology

AIM:To evaluate the prevalence of double negative(DN)sera and the mechanisms responsible for DN ***:Sera of inflammatory bowel disease patients treated with infliximab(IFX)were tested for drug/antibodies to infliximab(ATI)trough levels and the proportion of DN results was compared between a commercially available double antigen ELISA(with labeled IFX as the detection antibody)and an antilambda ELISA(with anti-human lambda chain detection antibody).Repeat testing with lower than customary serum dilution(1:10)was *** with DN status were matched with IFX+/ATI-controls and were followed-up for subsequent development of nontransient ATI to investigate if DN status precedes ***:Of 67 sera obtained at time of loss of response,only 6/67(9%)were DN by anti-lambda ELISA compared to 27/67(40%)with double antigen ELISA(P<0.001,Fisher’s Exact test).Of the latter27 sera,22%were also DN by anti-lambda ELISA,whereas 44%were actually IFX positive(IFX+ATI-),30%were ATI positive(IFX-ATI+)and 4%were double positive(IFX+ATI+).Re-testing using a 1:10 dilution converted most DN results into IFX+and/or ATI+*** with DN status had shorter survival free of non-transient ATI compared with matched controls(log rank test,P<0.001).In 9/30(30%)of these patients,non transient ATI occurred before and after the event at which the DN serum was obtained,supporting the view that a DN result may represent aparticular time-point along the two curves of ATI titer rise and infliximab drug level ***:DN status may result from false negative detection of IFX or ATI by double antigen ELISA,suggesting a transitional state of low-level immunogenicity,rather than non-immunological clearance.

关键词： Inflammatory bowel disease Biological therapy Infl

Crowdfunding Effort Identifies the Causative Mutation in a Patient with Nystagmus,Microcephaly,Dystonia and Hypomyelination

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Genetics and Genomics 2015年第2期42卷 79-81页

作者： Ofer Isakov Dorit Lev Lubov Blumkin Gershon Celniker Esther Leshinsky-Silver Noam shomron Sackler School of Medicine Tel Aviv University Metabolic-Neurogenetic Clinic Wolfson Medical Center Institute of Medical Genetics Wolfson Medical Center Pediatric Neurology Unit Wolfson Medical Center Molecular Genetic Laboratory Wolfson Medical Center

Crowdfunding refers to the online gathering of finance via numerous small donations from individual supporters （the ＂crowd＂） in order to fund a service, project or cause from various fields including business, arts, medicine and science （Sisler, 2012; Cameron et al., 2013; Weigmann, 2013; Wheat et al., 2013）. Crowdfunding platforms facilitate the interaction between organizations soliciting funding for their projects and the people who wish to support them. As prices of molecular testing plummet, utilizing crowdfunding in order to support genetic research becomes increasingly feasible （Cameron et al., 2013）. Whole Exome Sequencing （WES） has been used extensively for the purpose of identifying the genetic cause of rare mendelian diseases, uncovering novel mutations in previously implicated genes or identifying new disease- causing genes （Ng et al., 2009; Bamshad et al., 2011; Gilissen et al., 2011）.

关键词： PHENOTYPE EXPANSION SPECTRUM